Vivos Therapeutics, Inc. (VVOS) AI Stock Analysis

Vivos Therapeutics, Inc. is a medical technology company based in Littleton, Colorado, focused on developing and commercializing non-invasive, non-surgical, and non-pharmaceutical treatments for dentofacial abnormalities, obstructive sleep apnea, and snoring in adults. Its central offering is The Vivos Method, an integrated approach combining multidisciplinary care to address sleep apnea and dentofacial conditions. The company also provides the VivoScore Program, delivering screening tools and home sleep tests for pediatric and adult patients. Vivos primarily markets and sells its oral appliances and related diagnostic treatments directly to licensed healthcare professionals, especially general dentists across the United States and Canada.

Annual revenue grew at a 5-year CAGR of 5.9% from FY2020 through FY2025. After dipping 13.9% to $13.8M in FY2023, revenue recovered by 8.9% to $15.0M in FY2024 and expanded 16.0% to $17.4M in FY2025. Gross margin stood at 60.4% in FY2025, down from 74.6% in FY2021. Operating losses have persisted, with an operating margin of -114.1% and a net loss of -$21.2M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue totaled $20.9M, driven by quarterly revenue growth of 34.9% year-over-year, alongside a net profit margin of -121.8% and diluted EPS of -$1.88.

As of June 30, 2026, Vivos Therapeutics held $1.8M in cash and short-term investments against total debt of $12.1M, resulting in net debt of $10.4M. The company faces liquidity pressure, evidenced by a current ratio of 0.21 and negative shareholders' equity of -$3.8M out of $24.1M in total assets. Cash burn continues, with FY2025 operating cash flow of -$15.3M and free cash flow of -$17.6M after capital expenditures of $2.3M. In addition, the company's share count increased 1819.2% over 5 years.

At $0.13 per share, Vivos Therapeutics carries a market capitalization of $4.4M and an enterprise value of $14.8M. VVOS trades at a price-to-sales multiple of 0.2x and an EV-to-revenue multiple of 0.7x, both well below the median of its US-listed Healthcare peers, which trades at a price-to-sales multiple of 4.1x. Its price-to-book multiple is 6.9x. The stock has underperformed broader markets substantially, dropping 95.5% over the past year and 99.9% over five years, compared to gains of 16.8% and 83.0% for the S&P 500.

Wall Street coverage includes 2 Strong Buy ratings and 1 Hold rating among analysts. The mean price target is $2.12, representing an upside of 1515.8% above the last close of $0.13. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $21.8M and an EPS of -$1.34. For the next fiscal year, 3 analysts project revenue of $34.1M and an EPS of -$0.82. Vivos beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 18, 2026.

This page is an AI-written research summary of Vivos Therapeutics, Inc. (VVOS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VVOS income statement, VVOS balance sheet, VVOS key metrics, VVOS analyst forecast, VVOS chart. See the VVOS stock overview for the latest quote and news.